In yesterday’s Wall Street session, Mereo BioPharma Group plc (NASDAQ:MREO) shares traded at $1.21, down -5.47% from the previous session.
4 analysts cover Mereo BioPharma Group plc (NASDAQ:MREO), according to research data. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $5.00 and a low of $4.00, we find $4.00. Given the previous closing price of $1.28, this indicates a potential upside of 212.5 percent. MREO stock price is now 18.92% away from the 50-day moving average and 26.99% away from the 200-day moving average. The market capitalization of the company currently stands at $151.23M.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
The stock has received a hold rating from 0 analysts and a buy rating from 4. Brokers who have rated the stock have averaged $4.25 as their price target over the next twelve months.
There have been several recent changes in the stakes of large investors in MREO stock. A new stake in Mereo BioPharma Group plc shares was purchased by BOOTHBAY FUND MANAGEMENT, LLC during the first quarter worth $517,000. ACADIAN ASSET MANAGEMENT LLC invested $232,000 in shares of MREO during the first quarter. In the first quarter, WORTH VENTURE PARTNERS, LLC acquired a new stake in Mereo BioPharma Group plc valued at approximately $93,000. SEI INVESTMENTS CO acquired a new stake in MREO for approximately $71,000. PFG INVESTMENTS, LLC purchased a new stake in MREO valued at around $57,000 in the second quarter. In total, there are 74 active investors with 51.68% ownership of the company’s stock.
On Tuesday morning Mereo BioPharma Group plc (NASDAQ: MREO) stock kicked off with the opening price of $1.2800. During the past 12 months, Mereo BioPharma Group plc has had a low of $0.43 and a high of $1.85. The fifty day moving average price for MREO is $1.0244 and a two-hundred day moving average price translates $0.9524 for the stock.
The latest earnings results from Mereo BioPharma Group plc (NASDAQ: MREO) was released for Dec, 2022.
Mereo BioPharma Group plc(MREO) Company Profile
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.
Leave a Reply